Sign in
Back
American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis: executive summary
Journal article   Peer reviewed

American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis: executive summary

Paul S Jellinger, Donald A Smith, Adi E Mehta, Om Ganda, Yehuda Handelsman, Helena W Rodbard, Mark D Shepherd, John A Seibel and AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis
Endocrine practice, Vol.18(2), pp.269-293
2012-03
DOI: https://doi.org/10.4158/EP.18.2.269
PMID: 22507559

Abstract

United States - epidemiology Humans Male Motor Activity Combined Modality Therapy - economics Cost Savings Atherosclerosis - economics Atherosclerosis - etiology Lipids - blood Dyslipidemias - therapy Adult Female Dyslipidemias - economics Child Hypolipidemic Agents - adverse effects Risk Factors Insulin Resistance Health Care Costs Hypolipidemic Agents - economics Diet, Fat-Restricted Adolescent Dyslipidemias - metabolism Hypolipidemic Agents - therapeutic use Drug Monitoring Atherosclerosis - prevention & control Dyslipidemias - physiopathology Smoking Cessation

Metrics

4 Record Views
59 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Citation topics
1 Clinical & Life Sciences
1.68 Lipids
1.68.236 Statins
Web Of Science research areas
Endocrinology & Metabolism
ESI research areas
Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Details